Navigation Links
HRT-breast cancer risk stays same, regardless of family history
Date:5/19/2009

The risk of developing breast cancer due to taking hormone replacement therapy appears to be the same for women with a family history of the disease and without a family history, a University of Rochester Medical Center study concluded.

The study, published online this week in the journal Epidemiology, adds to the evolving picture of what factors, either alone or in combination, boost breast cancer risk among postmenopausal women. It also refutes the notion, held by many in the medical community, that a familial predisposition to breast cancer enhances the carcinogenic effects of estrogen.

"Although we know that family history is a risk factor, we don't know yet what it is about family history that conveys the risk," said Robert E. Gramling, M.D., D.Sc., assistant professor of Family Medicine and of Community and Preventive Medicine at URMC. "Some have proposed that it might be an increased sensitivity to estrogen, but our data did not support that notion. In fact, this study suggests the causal pathway based on family history is probably not estrogen sensitivity."

Researchers analyzed data from the Women's Health Initiative randomized trial, which followed 16,608 postmenopausal women, ages 50 to 79, who took hormone replacement therapy (HRT) or a placebo pill between 1993 and 2002. Among the participants, 349 cases of invasive breast cancer occurred during a mean follow-up period of 5.6 years.

Gramling divided the data into subgroups and studied the direct interaction between the contributions that the two risk factors (HRT and family history) had on breast cancer risk among postmenopausal women. The results showed only a negligible degree of interaction, suggesting that HRT conveys no greater breast cancer risk to women with, versus without, a first-degree family history of breast cancer (i.e. breast cancer in a mother, sister or daughter).

The study does have limitations, the authors noted. First, the women had a short period of exposure to hormone treatment and a short follow-up period. It is possible that longer exposure to HRT would have generated different results, the study said. Also, researchers asked women about family history of breast cancer only at the start of the WHI study. Finally, the majority of women who enrolled in the WHI trial represented a more educated and somewhat healthier population, and it is unknown how this might have influenced any interaction between hormone therapy and family history.

The WHI study gained notoriety when it was stopped abruptly in 2002, after data safety monitoring experts found hormonal therapy did not provide many of the benefits doctors and patients expected, and also carried some unforeseen risks.

Since then, many postmenopausal women have been wary of using HRT. Scientists have continued to study the data for nuances that will lead to a more complete picture. Gramling believes his research adds a new dimension to the large body of information now available on HRT and breast cancer.

"The decision to use hormonal therapy, even for a short period of time, is very difficult for many women," Gramling said. "We hope our data will provide postmenopausal women and their physicians more evidence to consider when weighing the risks versus benefits."


'/>"/>

Contact: Leslie Orr
Leslie_Orr@urmc.rochester.edu
585-275-5774
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences
2. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
3. LIFE 10th Anniversary Event Delivers Big Names and Big Dollars for Breast Cancer Fight
4. Research reveals molecular pathway behind invasive prostate cancers
5. Study Cites Gains in Gall Bladder Cancer Treatment
6. Poor Women Seem to Be Skipping Breast Cancer Drugs
7. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
8. Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
9. NCCN Updates Guidelines for Central Nervous System (CNS) Cancers
10. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
11. The future of personalized cancer treatment: An entirely new direction for RNAi delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... ... 20, 2017 , ... Lice Troopers, the lice removal company based in South ... since the holiday season. , “It happens every year around this time,” says ... taking photos, which is the head-to-head gateway that lice need to spread.” , As ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is ... as an educator interacting with countless women who had little knowledge of the female ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda ... will release results for the fourth quarter of 2016 on Wednesday, ... ... at 4:30 PM ET on Wednesday, February 15, 2017, during which ... results and other corporate activities. To participate in the conference call, ...
(Date:1/19/2017)... -- Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical ... new additions to its senior leadership team: W. ... Daniel Geffken as interim Chief Financial Officer. ... Pharm.D. has been promoted to Chief Clinical Development Officer. ... and Daniel to our management team, as both will ...
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
Breaking Medicine Technology: